| ASSET | YEAR | % RETURN |
|---|---|---|
Erasca (ERAS) | 2026 | 347.44% |
Immunitybio (IBRX) | 2026 | 253.47% |
Fastly, Inc Class A Common Stock (FSLY) | 2026 | 213.26% |
AXT (AXTI) | 2026 | 174.07% |
Enliven Therapeutics (ELVN) | 2026 | 143.81% |
Ultra Clean (UCTT) | 2026 | 142.92% |
Tango Therapeutics (TNGX) | 2026 | 139.77% |
Applied Opt (AAOI) | 2026 | 137.58% |
Alumis (ALMS) | 2026 | 132.65% |
Day One Biopharmaceuticals (DAWN) | 2026 | 130.57% |
Dianthus Therapeutics (DNTH) | 2026 | 105.69% |
Viavi Solutions (VIAV) | 2026 | 95.57% |
Valaris (VAL) | 2026 | 90.85% |
Sasol (SSL) | 2026 | 85.85% |
Adecoagro (AGRO) | 2026 | 85.61% |
Amprius Technologies (AMPX) | 2026 | 83.67% |
Chemours (CC) | 2026 | 81% |
Argan (AGX) | 2026 | 80.44% |
DigitalOcean (DOCN) | 2026 | 80.26% |
Nektar Therapeutics (NKTR) | 2026 | 78.18% |
Arcellx (ACLX) | 2026 | 76.57% |
Calumet Specialty Products Partners (CLMT) | 2026 | 74.96% |
Par Pacific (PARR) | 2026 | 74.6% |
FormFactor (FORM) | 2026 | 74.43% |
Noble (NE) | 2026 | 73.71% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.
